Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 3/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | PPARD | Q03181 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 1/20 | 0.50 |
| ▸ | LDHA | P00338 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL806723 | 0.83 | CA2 (0.63) | TTRALOX15ALOX12PPARGPPARD | |
| SCHEMBL13718998 | 0.83 | TTR (0.45) | TTRPOLB | |
| SCHEMBL14468310 | 0.82 | TTR (0.73) | TTRPPARGPPARDPPARAKMT2A | |
| SCHEMBL13719319 | 0.81 | TTR (0.48) | TTRKMT2A | |
| SCHEMBL3458007 | 0.81 | TTR (0.71) | TTRPPARGPPARDPPARAALDH1A1 | |
| SCHEMBL2799091 | 0.81 | TTR (1.00) | TTRPPARGPPARDPPARAALDH1A1 | |
| SCHEMBL8429041 | 0.81 | TTR (0.71) | TTRPPARGPPARDPPARAKMT2A | |
| SCHEMBL21803812 | 0.80 | TTR (0.58) | TTRALOX15PPARGPPARDPPARA | |
| SCHEMBL5018761 | 0.80 | MEN1 (0.58) | KMT2AALDH1A1 | |
| SCHEMBL27936114 | 0.79 | PDE4D (0.48) | TTRALOX15ALOX12LDHAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579479-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-25 | — | — | US | disclosed |
| US-7241780-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOLS-MYERS SQUIBB COMPANY (US) | 2007-07-10 | — | — | US | disclosed |
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | GPR119, LIPC, ACACA | TTR 4200/4885ALOX15 1304/4885ALOX12 1133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.